The estimated Net Worth of Yao Wenqing is at least $18.5 million dollars as of 28 June 2021. Wenqing Wenqing owns over 27,194 units of Incyte stock worth over $5,939,270 and over the last 10 years he sold INCY stock worth over $5,578,509. In addition, he makes $6,951,560 as Executive Vice President et Head of Discovery Chemistry at Incyte.
Wenqing has made over 17 trades of the Incyte stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 27,194 units of INCY stock worth $2,321,552 on 28 June 2021.
The largest trade he's ever made was selling 27,194 units of Incyte stock on 28 June 2021 worth over $2,321,552. On average, Wenqing trades about 5,547 units every 55 days since 2015. As of 28 June 2021 he still owns at least 94,080 units of Incyte stock.
You can see the complete history of Wenqing Wenqing stock trades at the bottom of the page.
Dr. Wenqing Yao, Ph.D., is Executive Vice President, Head of Discovery Chemistry of Incyte Corporation. He has served as Executive Vice President, Head of Discovery Chemistry since October 2014. Dr. Yao joined Incyte as Director, Chemistry in February 2002 and held roles of increasing responsibility at Incyte. Prior to joining Incyte, Dr. Yao held scientific research positions with DuPont Pharmaceuticals and Bristol-Myers Squibb Company from 1996 to 2002. Dr. Yao received his B.S. in chemistry from Xuzhou Normal University, his M.S. in organic chemistry from NanKai University and his Ph.D. in organic/medicinal chemistry from the University of Pennsylvania.
As the Executive Vice President et Head of Discovery Chemistry of Incyte, the total compensation of Wenqing Yao at Incyte is $6,951,560. There are 2 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.
Wenqing Yao is 56, he's been the Executive Vice President et Head of Discovery Chemistry of Incyte since 2014. There are 16 older and 10 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Yao's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... et Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: